The FDA will test and refine the quality management maturity program in 2024. The QMM won’t analyze product quality but will assess drug manufacturers’ processes, including a company’s commitment to quality, protocol to minimize supply disruptions, advanced pharmaceutical quality systems, technical excellence and employee engagement.
Pharmaceutical supply experts have long pushed for agencies to assess and publish quality metrics for drugmakers in an effort to quell harm from drug shortages.
The FDA said it plans to “recognize establishments that have advanced quality management practices and acknowledge establishments that strive to continually improve quality management practices,” as well as “identify areas where quality management practices can be enhanced and provide suggestions for growth opportunities,” according to the white paper.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
